NURO NeuroMetrix Inc.

NeuroMetrix Announces Participation at the 2016 Partners Connected Health Symposium

NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) reported today that it will be an active participant at the Connected Health Symposium on October 20-21 in Boston sponsored by Partners Healthcare. Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, will be a panelist for a discussion entitled: “New Wearables for Health and Wellness: Monitoring and Therapy.” In addition, NeuroMetrix will present a scientific poster entitled: “Sleep Phenotypes in Chronic Pain Suffers: Application of Machine Learning to a Large Database.” The Company will sponsor an exhibition providing information and demonstrations of its Quell® wearable technology for chronic pain at booth 132 at the Symposium.

"We are pleased to participate in the discussion about the role that health monitoring and therapeutic technologies are playing in reshaping healthcare,” said Dr. Gozani. “With over 30,000 Quell devices in the market and 2 million hours of patient data in the Quell Health Cloud, we are uncovering important trends related to sleep and the management of chronic pain.”

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About Partners Healthcare and Partners Connected Health

Partners Healthcare is a not-for-profit health care system that is committed to patient care, research, teaching, and service to the community locally and globally. Partners HealthCare Connected Health creates and validates technology-enabled solutions that empower patients and providers to transform health care. From ideation to research to program design and implementation, a multi-disciplinary team develops innovations that facilitate collaborative care, self-management, and improved quality. Partners collaborates with providers, patients, policy makers and industry to demonstrate the power of technology-enabled interventions in research studies and in “real-world” clinical and remote patient settings. The interventions designed and developed by Partners Connected Health focus on creating behavior change, generating efficiencies and improving the quality of care.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

EN
18/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuroMetrix Inc.

Neurometrix Inc: 1 director

A director at Neurometrix Inc sold 20,000 shares at 13.560USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable T...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle. "We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is co...

 PRESS RELEASE

NeuroMetrix Closes $3.5 Million Equity Offering

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company’s common stock closed on October 30, 2017 at $1.80 per share. Proceeds of the offering will be used for commercialization of Quell®, the Company's over-the-counter wearable device for relief of chronic pain and for general work...

 PRESS RELEASE

NeuroMetrix Reports Q3 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that pro...

 PRESS RELEASE

NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Resu...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 84863406. Internationally, the co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch